GW Pharmaceuticals (GWPH) had a good month in June. A host of further bullish factors appeared following the company's Q1 earnings.
My article in May detailed the promising pipeline and other bullish factors for the company. I will not repeat that in detail here.
The stock price has done well this year following the general COVID-19-induced market fall. This is illustrated below:
Source: Charles Schwab
The continuing good news should enable the stock to rise further leading up to the Q2 earnings announcement at the beginning of August. Confirmation of product approval for TSC (tuberous